ArticleJournal of neuro-oncology1996
Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines.
Article in Journal of neuro-oncology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 105 citations in OpenAlex.
- Key Genes Involved in the Beneficial Mechanism of Hyperbaric Oxygen for Glioblastoma and Predictive Indicators of Hyperbaric Oxygen Prolonging Survival in Glioblastoma Patients.Current medical science · 2024Article
- Hypoxia-induced one-carbon metabolic reprogramming in glioma stem-like cells.Life medicine · 2023Article
- Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches.Frontiers in oncology · 2022Review
- Multimodal Role of PACAP in Glioblastoma.Brain sciences · 2021Review
- UCP2 - Taking the heat out of P-glycoprotein?Cancer drug resistance (Alhambra, Calif.) · 2021Article
- Hyperbaric oxygen increases glioma cell sensitivity to antitumor treatment with a novel isothiourea derivative in vitro.Oncology reports · 2019Article
- Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma.Frontiers in oncology · 2019Article
- Hyperbaric oxygen as an adjunctive therapy in treatment of malignancies, including brain tumours.Medical oncology (Northwood, London, England) · 2016Review
- Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma.British journal of clinical pharmacology · 2016Review
- Article
- A patient-specific computational model of hypoxia-modulated radiation resistance in glioblastoma using 18F-FMISO-PET.Journal of the Royal Society, Interface · 2015Article
- Radiosensitization of malignant gliomas following intracranial delivery of paclitaxel biodegradable polymer microspheres.Journal of neurosurgery · 2014Article
- A high-throughput photodynamic therapy screening platform with on-chip control of multiple microenvironmental factors.Lab on a chip · 2014Article
- A miR-297/hypoxia/DGK-α axis regulating glioblastoma survival.Neuro-oncology · 2013Article
- The roles of hypoxia-inducible factors in regulating neural stem cells migration to glioma stem cells and determinating their fates.Neurochemical research · 2012Review
- Development of (99m)Tc-N4-NIM for molecular imaging of tumor hypoxia.Journal of biomedicine & biotechnology · 2012Article
- Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids.Journal of neuro-oncology · 2011Article
- Sensitivity to cisplatin in primary cell lines derived from human glioma correlates with levels of EGR-1 expression.Cancer cell international · 2011Article
- Article
- Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival.Clinical cancer research : an official journal of the American Association for Cancer Research · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent gliomas are most often treated by chemotherapy. However, these tumors typically acquire resistance to most drugs administered, and patients will usually die of recurrent tumor. Factors which may play a role include overexpression of putative multidrug resistance genes, such as the multidrug resistance gene 1 (MDR1), multidrug resistance associated protein gene (MRP), 06-alkylguanine, DNA alkyltransferase gene (06MT) and excision repair cross complementing gene 1 (ERCC1). Tumor hypoxia has also been shown to be associated with drug resistance in other soft tissue tumors. Since gliomas have regions of diminished oxygenation, and have clinical resistance to chemotherapy, the relationship between phenotypic resistance to chemotherapy after hypoxic exposure and expression of drug resistance genes was investigated in glioma cell lines (U373 MG, PFAT-MT). After a 24 hour exposure to hypoxia, drugs 1, 3-bis, 2-chloroethyl-1-nitrosurea (BCNU) and cis-diammine, dichloroplatinum II (CDDP) were administered, and cell survival was determined. Hypoxic exposure was associated with increased survival of the cell lines after administration of BCNU and CDDP, with resistance to BCNU 15 to 30-fold when compared to cells which did not undergo hypoxic exposure. Both tumor cell lines also showed some degree of resistance to CDDP, although not to the extent of BCNU (2 to 3-fold increased resistance). The expression of the drug resistance genes was found to be unchanged when comparing cells which had undergone hypoxic exposure and those which had not. Thus, hypoxic exposure is associated with substantial drug resistance in brain tumor cell lines. The lack of correlation between the induced phenotype and known drug resistance genes suggests other mechanisms may be acting in these tumors in hypoxic conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.